• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

24.14 -0.98 (-3.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,538,958
Open 25.05
Bid (Size) 24.00 (20)
Ask (Size) 24.55 (5)
Prev. Close 25.12
Today's Range 24.09 - 25.14
52wk Range 16.10 - 35.72
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know
September 26, 2025
During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent... 
Via Benzinga
Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market Session
September 26, 2025
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday. 
Via Benzinga
Topics Stocks

Performance

YTD
-27.2%
-27.2%
1 Month
-2.9%
-2.9%
3 Month
+21.2%
+21.2%
6 Month
+24.9%
+24.9%
1 Year
-11.8%
-11.8%

More News

Read More
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket
September 26, 2025
Via Benzinga
Topics Artificial Intelligence
Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary
August 18, 2025
Via Stocktwits
Earnings Scheduled For July 31, 2025
July 31, 2025
Via Benzinga
Earnings Scheduled For May 7, 2025
May 07, 2025
Via Benzinga
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
August 27, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug
July 31, 2025
Via Stocktwits
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday
July 31, 2025
Via Benzinga
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss
July 31, 2025
Via Chartmill
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
July 31, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio
July 29, 2025
Via Benzinga
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals
July 28, 2025
Via Stocktwits
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
July 28, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
July 24, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
July 18, 2025
Via Benzinga
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 15, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals
July 02, 2025
Via Benzinga
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
July 01, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
June 06, 2025
From Apellis Pharmaceuticals, Inc.; Sobi
Via GlobeNewswire
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 04, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts
May 22, 2025
Via Benzinga
Why Apellis Pharmaceuticals Wilted on Wednesday
May 07, 2025
Via The Motley Fool
Topics Earnings
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
May 07, 2025
Via Benzinga
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
May 07, 2025
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Apellis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Apellis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Apellis Pharmaceuticals, Inc. - Common Stock trade on?
Apellis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock is APLS on the Nasdaq Stock Market
What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?
The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 24.14
When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 10/13/25 04:00 PM ET
What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 2.81B
How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?
Apellis Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+7.15 (3.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap